You are here: Industry Insights > NICE

News List

NICE nod for Jazz’ AML chemo pharmatimes
November 09, 2018
“I am pleased that NICE has recognised the value of this medicine for adults with secondary AML. In time, it is expected to become the standard of care for this specific group of older AML patients.”
NICE turns down Sanofi's Caprelsa for rare thyroid cancer pharmafile
November 01, 2018
NICE has announced its recommendation to reject Sanofi’s Caprelsa (vandetanib) for use on the NHS in the treatment of medullary thyroid cancer (MTC) that either cannot be operated on or has metastasised to other areas of the body...
Novartis strike $40m deal with Chinese firm Cellular Biomedicine pharmafile
September 29, 2018
Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in the People’s Republic of China (PRC).
NICE rejects CAR-T therapy Kymriah for DLBCL in adults pharmafile
September 20, 2018
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma pharmatimes
September 20, 2018
The National Institute for Health and Care Excellence has turned down NHS funding for use of Novartis’ CAR-T therapy Kymriah in adults...
NICE says no to Kymriah for adult lymphoma despite offer on price biopharmadive
September 20, 2018
Novartis slashed the U.K. list price for Kymriah by nearly a quarter compared to the U.S. for treating ALL patients under 25 whose disease was refractory, in relapse post-transplant or in second or later relapse.
NICE nod for Novartis’ targeted skin cancer combo pharmatimes
September 18, 2018
The National Institute for Health and Care Excellence has backed NHS funding for Novartis’ oral targeted adjuvant combination therapy...
NICE u-turn approves funding for rare disease therapy Crysvita pharmatimes
September 14, 2018
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita...
MS Society launches petition against NICE’s rejection of Ocrevus The MS Society has launched a petition imploring t
September 14, 2018
The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche...
NICE rejects Opdivo for preventing melanoma recurrence pharmatimes
September 13, 2018
NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page